Cargando…

Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients

Rifaximin is a poorly absorbable antibiotic against hepatic encephalopathy (HE). This observational study aimed to elucidate the effect of rifaximin on intestinal permeability and gut microbiota in patients with decompensated cirrhosis. Thirty patients with decompensated cirrhosis were assessed by a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaji, Kosuke, Saikawa, Soichiro, Takaya, Hiroaki, Fujinaga, Yukihisa, Furukawa, Masanori, Kitagawa, Koh, Ozutsumi, Takahiro, Kaya, Daisuke, Tsuji, Yuki, Sawada, Yasuhiko, Kawaratani, Hideto, Moriya, Kei, Namisaki, Tadashi, Akahane, Takemi, Mitoro, Akira, Yoshiji, Hitoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235723/ https://www.ncbi.nlm.nih.gov/pubmed/32235367 http://dx.doi.org/10.3390/antibiotics9040145

Ejemplares similares

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
por: Kaji, Kosuke, et al.
Publicado: (2017)

Rifaximin enhances the L-carnitine-mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut-liver-muscle axis
por: Murata, Koji, et al.
Publicado: (2022)

Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis
por: Fujinaga, Yukihisa, et al.
Publicado: (2020)

Laser-cut-type versus braided-type covered self-expandable metallic stents for distal biliary obstruction caused by pancreatic carcinoma: a retrospective comparative cohort study
por: Kitagawa, Koh, et al.
Publicado: (2022)

Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients
por: Moriya, Kei, et al.
Publicado: (2019)

Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis
por: Tsuji, Yuki, et al.
Publicado: (2020)

TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats
por: Kaya, Daisuke, et al.
Publicado: (2019)

Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study
por: Akahane, Takemi, et al.
Publicado: (2020)

Efficacy of Underwater Endoscopic Mucosal Resection for Superficial Non-Ampullary Duodenal Epithelial Tumor
por: Furukawa, Masanori, et al.
Publicado: (2021)

Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis
por: Ozutsumi, Takahiro, et al.
Publicado: (2020)

Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity
por: Fujimoto, Yuki, et al.
Publicado: (2021)

Increased Endotoxin Activity Is Associated with the Risk of Developing Acute-on-Chronic Liver Failure
por: Takaya, Hiroaki, et al.
Publicado: (2020)

Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis
por: Nishimura, Norihisa, et al.
Publicado: (2021)

Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients
por: Takaya, Hiroaki, et al.
Publicado: (2019)

Association between Equol Production Status and Nonalcoholic Steatohepatitis
por: Akahane, Takemi, et al.
Publicado: (2021)

Thyroid‐stimulating hormone is an independent risk factor of non‐alcoholic fatty liver disease
por: Tahara, Kazuki, et al.
Publicado: (2019)

The Combination of Albumin–Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child–Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven Criteria
por: Takaya, Hiroaki, et al.
Publicado: (2021)

The Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity: Usefulness as a Prognostic Biomarker in Acute-on-Chronic Liver Failure
por: Takaya, Hiroaki, et al.
Publicado: (2023)

Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B
por: Tsuji, Yuki, et al.
Publicado: (2020)

Effect of L-carnitine on health-related quality of life in patients with liver cirrhosis
por: Sato, Shinya, et al.
Publicado: (2020)

Comparison of the efficacy and safety between palliative biliary stent placement and duct clearance among elderly patients with choledocholithiasis: a propensity score-matched analysis
por: Kitagawa, Koh, et al.
Publicado: (2021)

The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects
por: Takagi, Hirotetsu, et al.
Publicado: (2021)

Late-Evening Snack with Branched-Chain Amino Acid-Enriched Nutrients Does Not Always Inhibit Overt Diabetes in Patients with Cirrhosis: A Pilot Study
por: Nakanishi, Keisuke, et al.
Publicado: (2019)

Chronic Alcohol Consumption is Inversely Associated with Insulin Resistance and Fatty Liver in Japanese Males
por: Akahane, Takemi, et al.
Publicado: (2020)

Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells
por: Kitagawa, Koh, et al.
Publicado: (2020)

Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection
por: Sato, Shinya, et al.
Publicado: (2019)

Macrophage Activation Markers Predict Liver-Related Complications in Primary Biliary Cholangitis
por: Fujinaga, Yukihisa, et al.
Publicado: (2022)

Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis
por: Namisaki, Tadashi, et al.
Publicado: (2017)

ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma
por: Takaya, Hiroaki, et al.
Publicado: (2019)

Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis
por: Ogawa, Hiroyuki, et al.
Publicado: (2021)

Association between ADAMTS13 activity–VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma
por: Takaya, Hiroaki, et al.
Publicado: (2020)

ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability
por: Takaya, Hiroaki, et al.
Publicado: (2022)

Zinc Administration and Improved Serum Markers of Hepatic Fibrosis in Patients with Autoimmune Hepatitis
por: Moriya, Kei, et al.
Publicado: (2021)

VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma
por: Takaya, Hiroaki, et al.
Publicado: (2019)

Management of refractory cirrhotic ascites: challenges and solutions
por: Fukui, Hiroshi, et al.
Publicado: (2018)

Glycogenic Hepatopathy in Type 1 Diabetes Mellitus
por: Asada, Shohei, et al.
Publicado: (2017)

The association between sarcopenia and endotoxin in patients with alcoholic cirrhosis
por: Sato, Shinya, et al.
Publicado: (2021)

Enhanced liver fibrosis score as a surrogate of liver-related complications and mortality in primary biliary cholangitis
por: Fujinaga, Yukihisa, et al.
Publicado: (2021)

Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy
por: Moriya, Kei, et al.
Publicado: (2021)

Accuracy of Fibrosis-4 Index in Identification of Patients with Cirrhosis Who Could Potentially Avoid Variceal Screening Endoscopy
por: Ishida, Koji, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pa3qa0g18vssogr146ubujnn7g